AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Mereo BioPharma Group faces securities fraud investigation.
ByAinvest
Wednesday, Aug 13, 2025 11:49 am ET1min read
Pomerantz LLP is investigating claims of securities fraud against Mereo BioPharma Group plc on behalf of investors. The investigation concerns whether the company and its officers or directors have engaged in unlawful practices. The investigation was prompted by a press release from Mereo and its development partner Ultragenyx Pharmaceutical Inc. regarding the progress of the Orbit study evaluating UX143 for osteogenesis imperfecta.
NEW YORK, July 02, 2025 — Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, has initiated an investigation into claims on behalf of investors of Mereo BioPharma Group plc (NASDAQ: MREO). The investigation focuses on whether the company and its officers or directors have engaged in securities fraud or other unlawful business practices [1].The investigation was prompted by a press release issued by Mereo and its development partner Ultragenyx Pharmaceutical Inc. on July 9, 2025. The announcement stated that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis, expected around the end of the year [2]. Following this news, Mereo's American Depositary Receipt (ADR) price fell by $1.25 per share, or 42.52%, to close at $1.69 per share on July 10, 2025 [2].
Investors are advised to contact Danielle Peyton at Pomerantz LLP for more information or to join the class action. The contact details are 646-581-9980, ext. 7980 [1, 2, 3].
Mereo BioPharma Group plc is a biopharmaceutical company that develops medicines for rare diseases and cancer. The company is working on treatments like setrusumab for brittle bone disease and alvelestat for severe lung disease [4]. Despite the potential of the company's pipeline, recent market reactions suggest investor concerns about the company's practices and the progress of its clinical trials.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris, has a long history of recovering multimillion-dollar damages awards on behalf of class members. The firm is known for its expertise in securities class actions and has recovered numerous damages awards in the past [1, 2].
References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-biopharma-group-plc---mreo-302521606.html
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-biopharma-group-plc---mreo-302525782.html
[3] https://www.bakersfield.com/ap/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo/article_147bd3c8-62b9-5682-88e8-6c9e475da3aa.html
[4] https://finance.yahoo.com/news/mereo-biopharma-group-mreo-announced-134505525.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet